A few weeks ago, I wrote an article about a relatively new biotech company known as Prothena (NASDAQ:PRTA), which highlighted its development efforts towards a disease-modifying antibody treatment for amyloidoses, NEOD001. Since then, the stock has gained 25%, closing on June 19 with a price of $12.76 and a market capitalization of $223M. The company's shares have gained 85% since the Elan spin-out began trading publicly in late 2012. Yet, even with this impressive run, I believe Prothena still has upside based not only on its amyloidosis program, but on its strong pipeline of disease-modifying antibodies. Prothena's second program in development is PRX002, a treatment for Parkinson's disease, and the company is developing PRX003 as a potential treatment...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|